Facebook Twitter LinkedIn Google Plus RSS

Medicines Co. acquisition of ProFibrix depends on study

By ,

Parsippany-based The Medicines Co. has announced its intent to purchase Netherlands-based ProFibrix, based on the results of a trial of ProFibrix's powder to stop surgical bleeding.

According to the announcement, Medicines will pay ProFibrix a $10 million upfront option payment. If Medicines is satisfied with the Phase 3 clinical trial results of the powder and decides to proceed, it will purchase all the outstanding capital stock of ProFibrix at closing. Otherwise, Medicines may terminate the transaction with no further obligation to ProFibrix shareholders.

More From This Industry

Write to the Editorial Department at editorial@njbiz.com

Leave a Comment


Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
View Comment Policy